KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Non Operating Income (2016 - 2026)

West Pharmaceutical Services has reported Non Operating Income over the past 16 years, most recently at -$200000.0 for Q1 2026.

  • Quarterly Non Operating Income changed 0.0% to -$200000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$57.9 million through Mar 2026, down 1186.67% year-over-year, with the annual reading at -$51.2 million for FY2025, 5020.0% down from the prior year.
  • Non Operating Income was -$200000.0 for Q1 2026 at West Pharmaceutical Services, up from -$50.6 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $25.5 million in Q4 2023 and troughed at -$50.6 million in Q4 2025.
  • The 5-year median for Non Operating Income is -$950000.0 (2022), against an average of -$3.4 million.
  • Biggest five-year swings in Non Operating Income: surged 1259.09% in 2023 and later plummeted 16766.67% in 2025.
  • Tracing WST's Non Operating Income over 5 years: stood at -$2.2 million in 2022, then soared by 1259.09% to $25.5 million in 2023, then crashed by 101.18% to -$300000.0 in 2024, then plummeted by 16766.67% to -$50.6 million in 2025, then surged by 99.6% to -$200000.0 in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$200000.0, -$50.6 million, and -$6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.